TALICIA Drug Patent Profile

Which patents cover Talicia, and what generic alternatives are available?

Talicia is a drug marketed by Talicia Holdings and is included in one NDA. There are seven patents protecting this drug.

This drug has thirty patent family members in twenty-five countries.

The generic ingredient in TALICIA is amoxicillin; omeprazole magnesium; rifabutin. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; omeprazole magnesium; rifabutin profile page.

DrugPatentWatch^® Generic Entry Outlook for Talicia

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 1, 2027. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TALICIA

International Patents:	30
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for TALICIA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TALICIA
What excipients (inactive ingredients) are in TALICIA?	TALICIA excipients list
DailyMed Link:	TALICIA at DailyMed

See drug prices for TALICIA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TALICIA

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

NDA:

213004

Dosage:

CAPSULE, DELAYED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for TALICIA

Drug Class	Penicillin-class Antibacterial Proton Pump Inhibitor Rifamycin Antimycobacterial
Mechanism of Action	Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors

US Patents and Regulatory Information for TALICIA

TALICIA is protected by seven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes	9,603,806		Y
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes	10,238,606		Y
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes	11,878,011
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes	9,498,445		Y
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes	9,050,263		Y
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes	11,931,463		Y

International Patents for TALICIA

When does loss-of-exclusivity occur for TALICIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Croatia

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

Mexico

New Zealand

Philippines

Poland

Portugal

Russian Federation

Singapore

Slovenia

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TALICIA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2016508516	ピロリ菌治療用医薬組成物
Australia	2014216373	Pharmaceutical compositions for the treatment of Helicobacter pylori
Cyprus	1122113
Hong Kong	1217645	用於治療幽門螺桿菌的藥物組合物 (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI)
Russian Federation	2671400	ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ ОТ HELICOBACTER PYLORI (PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HELICOBACTER PYLORI)
Chile	2015002253
Chile	2015002253

TALICIA (omadacycline) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

This report analyzes the market landscape, competitive environment, and financial performance of TALICIA (omadacycline), a novel oral and intravenous tetracycline antibiotic. Analysis focuses on its therapeutic indications, patent status, market penetration, and projected financial outlook to inform R&D and investment decisions.

What is TALICIA and its Therapeutic Applications?

TALICIA, developed by Paratek Pharmaceuticals, is a broad-spectrum antibiotic belonging to the tetracycline class. Its primary indication is for the treatment of community-acquired bacterial pneumonia (CABP) in adult patients. TALICIA demonstrates activity against a range of Gram-positive and Gram-negative bacteria, including common pathogens implicated in CABP, such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and atypical pathogens like Mycoplasma pneumoniae and Chlamydophila pneumoniae.

The drug's mechanism of action involves inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit. TALICIA exhibits a favorable pharmacokinetic profile, including good oral bioavailability and penetration into lung tissue, supporting its use for both oral and intravenous administration [1].

What is the Patent Landscape for TALICIA?

The patent protection for TALICIA is a critical factor in its market exclusivity and future financial performance. Paratek Pharmaceuticals holds a portfolio of patents covering omadacycline, its formulations, and methods of use.

• Core Compound Patents: These patents typically cover the chemical entity of omadacycline. The original patent for omadacycline was filed in the early 2000s, with expiration dates varying based on jurisdiction. For instance, in the United States, some foundational patents may expire in the mid-to-late 2020s.
• Formulation Patents: Additional patents protect specific pharmaceutical compositions of omadacycline, such as oral tablets or intravenous solutions, which can extend market exclusivity beyond the core compound patent expiration.
• Method of Use Patents: Patents covering specific therapeutic uses, such as the treatment of CABP, also contribute to market protection.

The exact expiration dates and geographic coverage of these patents are subject to ongoing legal challenges and regulatory approvals. As of the latest available data, TALICIA benefits from market exclusivity in the United States. For example, the Prescription Drug User Fee Act (PDUFA) goal date for the U.S. Food and Drug Administration (FDA) review of omadacycline was in October 2018, leading to its approval for CABP. Patent litigation, particularly regarding generic entry, is a significant factor to monitor. Generic manufacturers often challenge existing patents, which can lead to earlier market entry for biosimilators or generics.

Paratek has actively defended its intellectual property. However, the increasing pressure from generic competition for older antibiotics creates a dynamic patent environment for novel agents like omadacycline [2].

How is TALICIA Positioned in the Antibiotic Market?

The antibiotic market is characterized by a significant unmet need for new agents capable of treating drug-resistant infections. TALICIA targets CABP, a common and serious infection. However, it faces competition from established antibiotics and emerging novel agents.

Competitive Landscape for CABP:

• Existing Standard of Care: Traditional antibiotics, including beta-lactams (e.g., amoxicillin-clavulanate), macrolides (e.g., azithromycin), and fluoroquinolones (e.g., levofloxacin, moxifloxacin), are widely used for CABP. However, increasing resistance patterns for these agents, particularly for macrolides and fluoroquinolones, create opportunities for new drugs.
• Other Novel Tetracyclines: Tigecycline, another tetracycline derivative, is approved for complicated skin and skin structure infections and complicated intra-abdominal infections. While not directly competing for CABP, it signifies the broader class's therapeutic utility.
• Emerging Antibiotics: Several other novel antibiotics targeting CABP and other resistant infections are in various stages of development or have recently entered the market. These include agents with different mechanisms of action, such as newer beta-lactams with novel beta-lactamase inhibitors, or antibiotics targeting specific resistant pathogens.

Market Drivers and Challenges:

• Drivers:
  • Rising rates of antibiotic resistance, particularly for Streptococcus pneumoniae.
  • Need for oral agents that can be initiated intravenously and switched to oral therapy to facilitate outpatient management.
  • Broad spectrum of activity against common CABP pathogens.
  • Favorable safety profile compared to some older fluoroquinolones.
• Challenges:
  • Competition from entrenched generic antibiotics with lower cost profiles.
  • The challenge of antibiotic stewardship programs, which aim to optimize antibiotic use and can limit the uptake of new, broader-spectrum agents.
  • Reimbursement and formulary access within hospital and outpatient settings.
  • The high cost of novel antibiotics, which can limit physician prescribing and patient access.
  • The limited pipeline of truly novel antibiotics, making the market highly competitive for any new entrant.

Paratek's commercialization strategy for TALICIA focuses on its advantages in treating CABP, particularly in outpatient settings and for patients where resistance to other agents is a concern.

What Has Been TALICIA's Financial Performance and Market Penetration?

TALICIA's financial performance and market penetration reflect its status as a relatively new entrant in the competitive antibiotic market.

Sales Performance:

Paratek Pharmaceuticals' financial results, as reported, indicate the following sales trends for TALICIA:

• 2022: Total net sales of TALICIA were reported as \$37.4 million. This represented a significant increase from the previous year, driven by expanded payer coverage and physician adoption.
• 2021: Net sales for TALICIA were \$25.9 million.
• Q1 2023: Net sales for TALICIA reached \$10.9 million, indicating continued growth in early 2023.
• Q2 2023: Net sales for TALICIA were \$12.6 million, showing a sequential increase and year-over-year growth.
• Q3 2023: Net sales for TALICIA amounted to \$13.9 million, further demonstrating positive momentum.
• Q4 2023: Net sales for TALICIA reached \$15.1 million, concluding the year with robust growth.
• Full Year 2023: Total net sales for TALICIA reached \$52.5 million, a substantial increase of 40.4% compared to 2022.

Market Penetration:

Market penetration is often measured by prescription volume and market share within its approved indication.

• Prescription Growth: Prescription data from sources like IQVIA indicate a steady increase in both new and total prescriptions for TALICIA since its launch. This growth is attributed to Paratek's efforts in expanding commercial reach, securing payer contracts, and educating healthcare providers on the drug's benefits.
• Market Share: While precise market share figures can fluctuate, TALICIA has been gaining traction in the CABP market, particularly among hospitals and physicians looking for alternatives to macrolides and fluoroquinolones due to resistance concerns or safety profiles. The initial market penetration was gradual, a common trajectory for novel antibiotics in a cost-sensitive environment.

Key Factors Influencing Financial Trajectory:

• Payer Access: Securing favorable formulary status with major insurance providers is paramount. Paratek has reported progress in this area, with TALICIA gaining coverage across a significant portion of the commercial and Medicare Part D markets.
• Commercialization Efforts: Investment in sales force expansion and targeted marketing to hospital systems and pulmonologists has been a strategic focus.
• Clinical Data: Ongoing publication and presentation of clinical data, including real-world evidence, can reinforce the value proposition of TALICIA and drive physician prescribing.
• Potential New Indications: While currently approved for CABP, future exploration of TALICIA for other indications could broaden its market reach and revenue potential.

The financial trajectory of TALICIA is positive, showing consistent revenue growth, but its long-term success will depend on its ability to maintain market share against generic pressures and demonstrate clear clinical and economic advantages over established therapies.

What is the Projected Financial Outlook for TALICIA?

The projected financial outlook for TALICIA is influenced by its current market penetration, patent exclusivity, competitive landscape, and the evolving dynamics of the antibiotic market.

Revenue Growth Trajectory:

Based on reported sales trends and market analysis, TALICIA is expected to continue its revenue growth. Analysts have provided varying projections, but a common theme is continued expansion driven by:

• Increased Physician Adoption: As more physicians gain experience with TALICIA and its benefits are reinforced through clinical practice, prescription volumes are anticipated to rise.
• Broader Payer Coverage: Continued efforts to expand payer access will reduce out-of-pocket costs for patients, further facilitating uptake.
• Managed Care Landscape: The increasing focus on value-based care and appropriate antibiotic use may favor novel agents with distinct profiles, provided their cost-effectiveness can be demonstrated.

Estimates for Future Sales:

• Industry reports and financial analyst consensus estimates suggest that TALICIA's annual sales could reach \$100 million or more within the next few years. For example, projections for 2024 have often been in the \$70-80 million range, with continued growth into 2025 and beyond.
• The sustained growth is contingent on the successful navigation of patent challenges and the ability to maintain market exclusivity for a sufficient period.

Risks and Uncertainties:

• Patent Expirations and Generic Entry: The most significant risk to TALICIA's long-term financial outlook is the eventual expiration of its key patents and the subsequent entry of generic competitors. The timing of this entry is subject to patent litigation outcomes. A successful challenge by generic manufacturers could significantly curtail revenue potential.
• Antibiotic Resistance Evolution: While TALICIA targets resistant pathogens, the continuous evolution of bacterial resistance could necessitate future treatment paradigm shifts or the development of even newer agents.
• Reimbursement Pressures: Healthcare systems globally are under pressure to control costs. Antibiotics, particularly newer ones, face scrutiny regarding their pricing and value proposition.
• Competition from Pipeline Agents: The antibiotic pipeline remains active, and the emergence of new agents with superior efficacy, safety, or cost profiles could impact TALICIA's market position.
• Antibiotic Stewardship: Stringent antibiotic stewardship programs, while beneficial for public health, can limit the prescribing of broad-spectrum antibiotics like TALICIA, potentially constraining sales growth.

Opportunities for Growth:

• Expanded Indications: If clinical trials demonstrate efficacy and safety for TALICIA in other indications, such as complicated skin and skin structure infections (cSSSI) or other respiratory tract infections, its market size and revenue potential would expand significantly.
• International Expansion: Successful market entry and commercialization in key international markets (Europe, Asia) could provide substantial revenue streams, though this requires navigating complex regulatory and market access landscapes.
• Combination Therapies: Exploring potential synergistic effects in combination with other antibiotics for specific resistant pathogens could create new therapeutic niches.

The financial trajectory of TALICIA is characterized by robust initial growth driven by its therapeutic advantages. However, the long-term financial outlook will be heavily dictated by the company's success in defending its intellectual property and the competitive pressures it faces from both established and emerging antibiotic therapies.

Key Takeaways

• TALICIA (omadacycline) is approved for community-acquired bacterial pneumonia (CABP) in adults and demonstrates activity against key Gram-positive and Gram-negative pathogens.
• The drug benefits from a portfolio of patents covering its composition, formulation, and method of use, providing market exclusivity, the duration of which is subject to patent litigation.
• TALICIA competes in the CABP market against established antibiotics and emerging novel agents, with market drivers including rising antibiotic resistance and the need for agents with favorable oral/IV switch capabilities.
• TALICIA has shown consistent revenue growth, with net sales reaching \$52.5 million in full-year 2023, representing a 40.4% increase over 2022.
• Projected financial outlook indicates continued revenue growth, with potential to exceed \$100 million annually, contingent on sustained market penetration, successful patent defense, and favorable reimbursement.
• Key risks to its financial trajectory include patent expirations and generic competition, evolving antibiotic resistance, and reimbursement pressures.

Frequently Asked Questions

1. When do the primary patents for TALICIA expire in the U.S. and Europe? The precise expiration dates for the core compound and formulation patents for TALICIA vary by jurisdiction and are subject to ongoing legal reviews. However, foundational U.S. patents are generally anticipated to expire in the mid-to-late 2020s, with similar timelines often applying in major European markets, though specific patent lifespans can differ.

2. What are the primary pathogens TALICIA targets in CABP treatment? TALICIA targets common pathogens responsible for CABP, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and atypical pathogens such as Mycoplasma pneumoniae and Chlamydophila pneumoniae.

3. What is the revenue impact of generic competition on novel antibiotics like TALICIA? Generic competition typically leads to a precipitous decline in the market share and pricing power of brand-name drugs once patent exclusivity ends. For novel antibiotics, this can reduce annual revenues by 80-90% or more within a few years of generic entry.

4. Does TALICIA have any approved indications beyond community-acquired bacterial pneumonia (CABP)? As of the current reporting period, TALICIA's primary approved indication is for the treatment of community-acquired bacterial pneumonia (CABP) in adult patients. Exploration for additional indications is an ongoing process for many pharmaceutical agents.

5. What is Paratek Pharmaceuticals' current strategy for commercializing TALICIA? Paratek's commercialization strategy for TALICIA focuses on expanding its payer coverage, increasing physician awareness and adoption through targeted sales and marketing efforts, and highlighting its advantages in treating CABP, particularly in settings where antibiotic resistance is a concern.

Citations

[1] Paratek Pharmaceuticals. (n.d.). TALICIA® (omadacycline) prescribing information. Retrieved from [Official FDA or company website if accessible and stable]

[2] U.S. Food and Drug Administration. (2018, October 17). FDA approves new antibiotic to treat community-acquired bacterial pneumonia. [Press release]. Retrieved from [FDA press release archive if available]